IM Cannabis (IMCC) Acquisitions (2021)

IM Cannabis (IMCC) posted quarterly Acquisitions of -$4.5 million for Q4 2021, down 18.74% quarter-over-quarter from -$3.8 million in Q3 2021.

IM Cannabis (IMCC) Acquisitions (2021) Analysis & Trends

IM Cannabis' Acquisitions history runs 1 years deep, the most recent figure standing at -$4.5 million for Q4 2021.

In Q4 2021, Acquisitions changed N/A year-over-year to -$4.5 million; the TTM figure through Dec 2021 stood at -$10.0 million (changed N/A YoY), while the FY2021 annual figure was -$10.0 million, changed N/A from the prior year.
Acquisitions for Q4 2021 stood at -$4.5 million, down from -$3.8 million in the prior quarter.
The five-year high for Acquisitions was $286015.9 in Q1 2021, with the low at -$4.5 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	-
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	-
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	-
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	IM Cannabis	554,496.00	-614,474.17	1.09 Mn	-

Download Data